Abstract The safety of hepatic resection is well documented, but outcome studies comparing right and left hepatic lobectomy are sparse, especially in the context of malignancy. This study analyzes the differences in outcomes between right and left hepatic lobectomy in patients with malignant diagnoses. All patients undergoing right and left hepatic lobectomies for malignancy were extracted from the National Surgical Quality Improvement Program (NSQIP) database (2005)(2006)(2007)(2008)(2009)(2010). The data was analyzed to determine differences in perioperative mortality and morbidity between the two groups. A total of 1680 patients who underwent right or left hepatic lobectomy for malignant diagnoses were identified. Patients undergoing right hepatic lobectomy had a four-fold increase in perioperative mortality, compared to left lobectomy (p<0.0001). Mortality in right lobectomy patients increased incrementally with age, with a 12-fold increase in patients>81 years of age. Patients undergoing right lobectomy also experienced a statistically significant increase in morbidity involving several systems (infectious, pulmonary, cardiac and renal). The results of our study demonstrate that patients undergoing right hepatic lobectomy for malignancy experience a significantly higher incidence of mortality and multisystem morbidity when compared to left lobectomy. This information will be crucial for pre-operative risk-stratification of patients undergoing hepatic resection for malignancy.
Introduction
The number of hepatic resections performed for malignant and benign diseases has been increasing, with the majority of these resections being performed for malignant diagnoses [1, 2] . Several previous studies have documented the safety of hepatic resections [3] [4] [5] , with mortality after major hepatic resections ranging between 2 and 5 % in high volume centers [1, [6] [7] [8] [9] . Although the safety of hepatic resection is well documented, the differences in outcomes after various types of major hepatic resections have not been well studied. The few published reports that analyzed the differences in outcomes between right and left hepatic lobectomy included healthy donor livers slated for transplantation, or consisted of patients that underwent extended resections. Karanjia et al. previously reported worse perioperative outcomes for right sided resections when compared to left sided resections [10] , however these authors combined extended right hepatectomy (which is technically and physiologically more challenging) with right lobectomy. There is a paucity of reports that have performed a detailed analysis of the differences in perioperative outcomes between right and left hepatic lobectomy in patients undergoing hepatic resection for malignancy [10, 11] .
The aim of this current study is to analyze the differences in mortality and morbidity between right and left hepatic lobectomy in patients undergoing hepatic resection for malignancy by utilizing the American College of Surgeons-National Surgical Quality Improvement Program (ACS-NSQIP) database.
Methods
All patients undergoing right hepatic lobectomy (primary CPT code 47130) and left hepatic lobectomy (primary CPT code 47125) were extracted from the ACS-NSQIP Participant Use Files (2005) (2006) (2007) (2008) (2009) (2010) . The subset of patients with primary and secondary malignancies of the liver were identified using ICD-9 diagnoses 155.0, 155.1 and 197.7 (155.0 and 155.1-primary liver malignancies, 197.7-secondary malignancies of the liver). Only patients with malignant diagnoses were considered for our analysis. Patients were further divided into two groups: right hepatic lobectomy and left hepatic lobectomy based on the type of hepatic resection.
Several demographic, preoperative patient-related and laboratory variables were analyzed to ensure that patients were evenly matched between the two groups of right and left hepatic lobectomies. Mortality was defined as all-cause mortality within 30 days of the procedure per the NSQIP database. The mean and standard deviations or median and ranges were used to describe the continuous variables, and percentages were reported for categorical variables. Chi-square test was used to perform univariate analyses of categorical variables whereas Mann-Whitney U test was used to compare continuous variables. Multivariate logistic regression was used to determine if right vs. left lobectomy are significant predictors of dichotomous outcomes (morbidity, mortality, and length of stay>10 days) after adjusting for covariates. Multivariate linear regression was employed to predict minutes of OR time in right vs. left lobectomy after adjusting for covariates. The multivariate model was adjusted for: age, gender, race, smoking status, BMI, Ascites, and CVA without neurological deficits. SAS software was used for the data analysis (SAS Institute Inc., Cary, NC). p values of <0.05 were considered significant.
Results

Patient Characteristics
Using the ACS-NSQIP database, 2311 patients who underwent a right or left hepatic lobectomy, between years 2005 and 2010 were extracted. Malignant diagnoses accounted for 73 % (n=1680) of the patients. Given the aims of the study, further analysis was limited to patients undergoing hepatic resection for malignant diagnoses only.
Nearly two thirds of all study patients (65 %) underwent right hepatic lobectomy. The mean age for the patients included in the study was 60.4 years. There were no differences in the mean age, BMI, gender distribution, preoperative use of cigarette smoking, alcohol consumption and preoperative weight loss between patients undergoing right or left hepatic lobectomy. Furthermore, the database was also checked for possible colectomy operations, coded as secondary procedures, done concomitantly at the time of liver resection. No differences were found in the incidence of colectomies performed during left or right hepatic lobectomies. Table 1 summarizes the demographic factors for patients undergoing right and left hepatic lobectomy for malignancy.
Preoperative comorbidities were comparable between the two groups with few exceptions. Patients undergoing left hepatic lobectomy had a higher prevalence of ascites preoperatively than those who underwent right hepatic lobectomy (2.18 vs. 0.89 %, p=0.029). However, patients undergoing left hepatic lobectomy had fewer episodes of cerebrovascular attacks with no neurological deficits than right hepatic lobectomy patients (0.54 vs. 1.86 % p=0.033). In addition, there were no significant differences in the available preoperative laboratory values between the two groups. Tables 2 and 3 summarize the preoperative comorbidities and mean laboratory values for patients undergoing right and left hepatic lobectomy for malignancy.
Perioperative Outcomes
Overall Mortality and Morbidity
The overall 30-day mortality and morbidity for the entire cohort of patients (n=1680) who underwent right or left hepatic lobectomy for malignancy was 3.39 % and 32.5 % respectively. Right hepatic lobectomy was associated with significantly higher 30-day mortality when compared to left hepatic lobectomy (4.52 vs. 1.09 % respectively, p<0.001). The influence of age on 30-day mortality within the two groups of right and left hepatic lobectomy, was analyzed by dividing the patient's age into quintiles (<50, 51-60, 61-70, 71-80 and >81 year of age) (Fig. 1 ). For patients undergoing right hepatic lobectomy, increasing age was associated with a significant increase in 30-day mortality (0.5 % for <50 years vs. 17.65 % for patients over 81 years of age, p<0.001). In contrast, increasing age was not associated with significant increase in 30-day mortality for patients undergoing left hepatic lobectomy (0.9 % for <50 years versus 1.43 % for >81 years of age, p=0.968).
On univariate analysis right hepatic lobectomy was associated with a higher incidence of a) overall morbidity b) infectious complications such as organ space infections and sepsis c) respiratory complications such as re-intubation, pulmonary embolism and failure to wean from ventilator lasting>48 h d) renal insufficiency and e) cardiac arrest. Similarly, right hepatic lobectomy was associated with longer operative times and prolonged length of stay. The worse outcomes associated with right hepatic lobectomy maintained significance on multivariate analysis. Tables 4 and 5 summarize the univariate and multivariate analyses of perioperative morbidity and 30-day mortality when comparing right vs. left hepatic lobectomy for malignancy.
Discussion
There are few reports that have performed a thorough analysis of the differences in perioperative outcomes between the right and left hepatectomy in patients undergoing hepatic resection for malignant diagnoses. The few reports published [10] [11] [12] [13] are either from single institutions with a small number of patients or included only living donor hepatectomy with healthy livers that does not lend to general applicability. Karanjia et al. [10] compared right and extended right hepatectomy to all other liver resections and did not include a direct comparison between right and left hepatic lobectomy. Similarly the study of Zeyneloglu et al. [11] and Umeshita et al. [12] compared right versus left hepatectomy for living donor liver transplantation in younger and healthy patients which again precludes generalization to patients with malignancy who often have multiple co-morbidities. This current study however, is a detailed analysis of the differences in perioperative outcomes between right and left hepatic lobectomies in patients undergoing hepatic resection with a specific emphasis only on malignant diagnoses by using the ACS-NSQIP database.
The results of our study demonstrate that right hepatic lobectomy is associated with a statistically significant higher rate of perioperative morbidity and 30-day mortality when compared to left hepatic lobectomy. Additionally, we noted that with increasing age, the 30-day mortality rate continued to rise in patients undergoing right hepatectomy. This age-based gradient effect on worsening 30-day mortality was evident only in patients undergoing right hepatectomy. In patients older than 81 years of age, the mortality after right hepatic lobectomy was found to be 16.75 % when compared to left hepatic lobectomy (1.43 %). These results are consistent with findings of the study by Tzeng et al. [14] which reported a higher mortality rate for patients greater than 75 years of age. Although their study documented a higher mortality rate in elderly patients, they did not perform a direct comparison of detailed perioperative outcomes between right and left hepatic lobectomy. In addition our study also highlighted an agebased gradient negative effect on 30-day mortality.
Patients undergoing right hepatic lobectomy were also noted to have a significantly higher post-operative morbidity rate than those undergoing left hepatic lobectomy. This higher morbidity extended across several systems such as infectious, pulmonary, renal and cardiovascular system. Right hepatic lobectomy patients in addition experienced a higher reoperation rate and longer length of stay. Since the current study was a descriptive study of the database, we can only speculate on the potential causes of increased 30-day mortality and morbidity after right hepatic lobectomy. It is likely that an increase in the rate of infectious, respiratory, renal and cardiac complications seen in patients undergoing right hepatic lobectomy could contribute to the increased mortality. Several other studies have noted the higher rate of pleural effusions, venous thromboembolism in patients undergoing right hepatic lobectomy [15] [16] [17] . Furthermore, it is known that morbidity and mortality after hepatic resection for malignancy is strongly associated with volume of the future liver remnant [18] . It is likely that the smaller future liver remnant following right hepatic lobectomy contributes to the worse perioperative outcomes as echoed by many other studies involving living donors undergoing right hepatectomies [13, 19, 20] . Given the limitations of the ACS-NSQIP database we could not factor in the details on the size of future liver remnant or rates of post-hepatectomy liver failure. In addition it has been shown that longer operating time incrementally increases multisystem morbidity, as well as mortality, with an effect more noticeable in the elderly population as seen in a study of 7696 major surgical procedures [21] . Similar to the published literature, we also noted that right hepatic lobectomy was associated with longer operative times which could contribute to the worse outcomes in our study.
The difference in outcomes between right and left hepatic lobectomy can have a significant bearing on several aspects of our clinical practice. An important aspect relates to obtaining consent for hepatic resections. In our discussions with the patients we generally quote the acceptable mortality rate of low-single digits for any type of lobectomy regardless of the laterality and age. The findings of our study suggest that quoting a uniform blanket mortality rate does not reflect the true mortality rates for the two operations, particularly in elderly patients. Instead, in our discussions with our patients we should highlight the differences in mortality and morbidity based on the laterality of hepatic lobectomy and age. However, these findings need to be validated in other studies.
There are several strengths associated with this study. The data analyzed in this report includes a large number of patients derived from several hospitals across the nation, which attests to the generalizability of the study findings. A large database Fig. 1 Representation of the 30-day mortality of right and left hepatic lobectomy across different age categories such as that of NSQIP, which takes into account more than 400 academic and non-academic institutions, provides the benefit of obtaining a more generalizable understanding of national outcomes of hepatectomies rather than looking at outcomes from single institutional reports which may not be as representative. Secondly, patients in the groups of right and left hepatic lobectomy were evenly matched for demographics, general variables, functional status, pre-operative co-morbidities and pre-operative laboratory values specific for hepatic and renal function. Finally, the overall 30-day mortality and morbidity rate noted for the entire cohort of patients was 3.12 and 32.11 % respectively, which is congruent with the currently accepted standards and similar to other seminal published reports [6, 22, 23] . This similarity in the rates of mortality and morbidity attests to the robustness of the included data, which thereby adds strength to the conclusions derived from this study. A study of this kind that utilizes a national database has several limitations. The study does not include data on the specific type of malignant diagnosis or extent of disease such a tumor burden etc. The current study does not include any information on preoperative chemotherapy, which can have an influence on perioperative outcomes following hepatic resection for malignancy. Although we were able to control for some of the pre-operative laboratory values that signify hepatic and renal function, crucial information on the size of future liver remnant was not available for inclusion. It is also likely that some left lateral hepatectomies may have been miscoded as left hepatic lobectomy contributing to the better outcomes. Nonetheless, since NSQIP is a surgical database that is maintained by surgeons with an institutional surgical champion the errors should be minimal. Lastly, we were unable to analyze the influence of the type of operative approach (open, laparoscopic or robotic) on perioperative outcomes.
In summary, the results of our study demonstrate that patients undergoing right hepatic lobectomy for a malignant diagnosis have significantly worse outcomes when compared to left hepatic lobectomy. This includes a significantly higher mortality rate, which is worse in the elderly. Patients undergoing right hepatic lobectomy are also noted to have a higher post-operative morbidity rates that affect several systems. These findings need to be validated in other studies. Efforts directed at improving outcomes and controlling costs in patients undergoing hepatic resections for malignancy need to be cognizant of this vital information.
